I had my primary, stage 2 diagnosis in 2010, reoccurence mbc March 2022, several tumours in my right lung.
Following failure on ribociclib, i was moved to Ibrance, faslo and letrozole in sept 22, stable since, ca153 marker in normal range.
My question here is for folks who may be able to comment on the correlation between ki67 levels and progression whilst on cdks. I recall recently reading of a 'friend' here who was having a long run on ibrance but with a ki67 level of just 1%. Mine is >30% so aggressive, (as I understand.) Wondering if anyone here can comment on correlation between ki levels and treatment failure?
Many thanks
Written by
Kahe
To view profiles and participate in discussions please or .
I’m not sure. I had a grade 3 (aggressive) Pleomorphic lobular and think my ki67 with that one was 20% and I’ve been stable on palbo Letrozole for >3 yrs so far.Hopefully you’ll get other replies. Maybe it’s the oestrogen related aspects that are more significant.
I'm on Palbociclib, Fulvestrant, plus Denosumab for 2 years. I'm in the UK and I never hear about markers, they're only interested in neutrophils. I know markers are often considered in the US, and it seems in Ireland. Sorry I can't comment, due to differences in treatment. May you long remain stable.
Since when has that Ki-67 level been measured? Since 2010?In the early stage, my mother's Ki-67 was 38. Eight years later, at recurrence, it was 22, and after six more years, in liver metastases, it was 18.
I'm not sure there is a correlation. From my understanding KI-67 determines how aggressive the cancer is but does not determine treatment. The OncotypeDX provides some course of treatment and indicates possible treatment effectiveness. I have yet to read anything that indicates treatment failures correlate to KI-67 numbers. My only suggestion would be to review any food, lifestyle or supplement interactions or any food, lifestyle or supplement that might enhance the effeteness. God Bless!
I believe the Ki-67 is used initially as prognostic indicator. I read this on Very well Health, "For breast cancer, Ki-67 is one of the main tumor biomarkers that your healthcare provider will check for when diagnosing, staging, and monitoring the cancer." I don't believe though the Ki- 67 alone determines treatment. It's just one in several diagnostic tests that oncologists use to make decisions but a low Ki-67 when there's been tumor progression anyway probably isn't a determining factor then for treatment. Mostly, it indicates the aggressiveness vs slow growth in cancer. All cancers can progress despite a low level of Ki-67. It's just my opinion on this, some else may have better information on it.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.